2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 61

Advocating for Pediatric Rheumatology Care in the Mid-Canadian Provinces: Large Geographic Area, Large Pediatric Population, Low Number of Pediatric Rheumatologists and Allied Health Workers Identified As Unique Challenges
Abstract Number: 1859

Age-Specific Predictors of Mortality in SLE
Abstract Number: 1936

Ageism, Fear, and Competing Co-Morbidities – Why Older Patients May Not Seek Care for Restricting Back Pain: A Qualitative Study
Abstract Number: 2140

Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis
Abstract Number: 283

Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis
Abstract Number: 2322

Aim for Better Gout Control: A Retrospective Analysis of Preventable Hospital Admissions for Gout
Abstract Number: 1199

Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Abstract Number: 2442

Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians
Abstract Number: 160

All Men with Gout Should be Screened for Erectile Dysfunction
Abstract Number: 960

Allogeneic Mesenchymal Stem Cell Transplantation for Lupus Nephritis Patients Refractory to Conventional Therapy
Abstract Number: 2185

Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2
Abstract Number: 2695

Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab
Abstract Number: 1737

Altered Phenotype and Function of Senescent Regulatory T Cells in Rheumatoid Arthritis
Abstract Number: 2845

Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis
Abstract Number: 1498

ALX-0061, an Anti-IL-6R Nanobody^®foruse in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].